<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948608</url>
  </required_header>
  <id_info>
    <org_study_id>S-20160094</org_study_id>
    <secondary_id>R-144-A4136</secondary_id>
    <nct_id>NCT02948608</nct_id>
  </id_info>
  <brief_title>Clinical Characteristics of Importance to Outcome in Patients With Spondyloarthritis</brief_title>
  <official_title>Effectiveness and Patient-reported Outcomes in Patients With Spondyloarthropathies Treated With Biological Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Svendborg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parker Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spine Centre of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Svendborg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate extra-articular manifestations, pain mechanisms,
      patient-reported outcomes, comorbidities and association between these conditions in patients
      with spondyloarthropathy (SpA) treated with Biologics. Further, to assess the predictive
      value of baseline pain profile on treatment outcome after ≥ 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with spondyloarthropaty, who initiate or switch biologics in routine care due to an
      active disease state, will be enrolled in this observational study.

      The overall aim is to investigate extra-articular manifestations, pain mechanisms and
      patient-reported outcomes and elucidate if these factors - independently or by interaction -
      influence treatment response after ≥ 3 months. Patients will have a baseline visit, an eye
      examination and a follow up visit after ≥ 3 months. Clinical examinations will be performed
      at both time points and include:

        1. Clinical examination (the spinal movement)

        2. Assessment of pain mechanisms by clinical evaluation (BASDAI, tender points,) and pain
           questionnaires (PainDETECT).

        3. The SPARCC Enthesitis Index will be used to enthesitis count.

        4. Interview and questionnaires regarding lifestyle, comorbidity, function and quality of
           life

        5. Blood samples

        6. Urine samples

        7. Stool samples

      Clinical as well as patient-reported and observer-based outcomes will be described for the
      overall study population and the prognostic influence of extra-articular manifestations,
      comorbidity and pain mechanisms will be analysed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ankylosing Spondylitis Disease Activity Index BASDAI 50 %</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
    <description>composite measures of improvement in disease state (50% improvement)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Ankylosing Spondylitis Disease Activity Score (ASDAS)</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
    <description>composite measures of improvement in disease state</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To analyse the influence of PDQ score on the treatment response</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
    <description>we analyse if the painDETECT questionnaire score (PDQ) at baseline can influence on treatment outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterisation of the extra-articular manifestations in SpA patients</measure>
    <time_frame>at baseline and ≥ 3 months from baseline</time_frame>
    <description>To characterise the extra-articular manifestations according to ASAS criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Bath Akylosing Spondylitis Functional Index (BASFI)</measure>
    <time_frame>≥ 3 month from timeline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Spondylitis Consortium of Canada enthesitis score (SPARCC)</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in score of Medical Outcomes Study Questionnaire (SF-36) for mental and physical Health</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in plasma calprotectin (microg/L)</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the Simple Clinical Colitis Activity Index (SCCAI)</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
    <description>composite measures of improvement in disease state</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the Harvey Bradshaws Activity Index (HBAI)</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
    <description>composite measures of improvement in disease state (Crohns disease)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fecal calprotectin (mg/kg)</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in C-Reactive Protein, CRP (mg/L)</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Visual Analogue Scale (VAS) (0-100 mm) of fatigue</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Visual Analogue Scale (VAS) (0-100 mm) of fatigue of pain</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Visual Analogue Scale (VAS) (0-100 mm) of global disease impact</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Withdrawal of treatment due to adverse event during the study period</measure>
    <time_frame>≥ 3 month from baseline</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Spondyloarthropathy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A Biobank will be established in connection with the routine blood samples taken at baseline
      (~ 90 ml). The blood samples will be handled and registered by research laboratory
      technicians at the laboratory department, and stored at Odense University Hospital, Denmark
      (in the cold store)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ≥ 18 years and diagnosed with any disease of the SpA spectrum, and about to initiate or
        switch biological treatment. We use the Assessment of Spondyloarthritis International
        Society (ASAS) criteria for SpA, and the Modified New York criteria for ankylosing
        spondylitis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with SpA

          -  ≥18 years of age at time of consent

          -  Ability and willingness to give written informed consent and to meet the requirements
             of this protocol

          -  Patients must have a history of active disease and a BASDAI &gt;40 (10-100) or elevated
             C-reactive protein, despite current or previous NSAIDs therapy

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  No consent

          -  Pregnancy

          -  Active or latent TB

          -  Diagnosed Human immunodeficiency virus

          -  Diagnosed hepatitis

          -  Current or past malignant disease

          -  Recurrent or chronic infection (viral, fungal or bacterial)

          -  Multiple sclerosis

          -  Heart failure (NYHA class III/IV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inger Marie J Hansen, MD, DmSci</last_name>
    <role>Study Chair</role>
    <affiliation>Svendborg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rikke A Andreasen, MD</last_name>
    <phone>+45 63202506</phone>
    <email>Rikke.asmussen@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inger Marie J Hansen, MD, DmSci</last_name>
    <phone>+45 63202506</phone>
    <email>inger.marie.jensen.hansen@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital, Svendborg Hospital</name>
      <address>
        <city>Svendborg</city>
        <zip>5700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rikke A Andreasen, MD</last_name>
      <phone>+45 63202506</phone>
      <email>Rikke.asmussen@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Inger Marie J Hansen, MD, dmSci</last_name>
      <phone>+45 63202506</phone>
      <email>inger.marie.jensen.hansen@rsyd.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Svendborg Hospital</investigator_affiliation>
    <investigator_full_name>Rikke Asmussen Andreasen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>spondyloarthropathy</keyword>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>spinal diseases</keyword>
  <keyword>spondylitis</keyword>
  <keyword>spondylarthritis</keyword>
  <keyword>psoriasis</keyword>
  <keyword>uveitis</keyword>
  <keyword>joint diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthropathies</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

